A comparative study of transcutaneous interferential electrical stimulation plus behavioral therapy and behavioral

Seyedeh-Sanam Ladi-Seyedian1, Lida Sharifi-Rad2, Navid Manouchehri3

  • 1Department of Pediatric Surgery, Pediatric Center Excellence, Children's Hospital Medical Center, Tehran University of Medical Sciences, Tehran, Iran (IRI); Universal Scientific Education and Research Network (USERN), Tehran, Iran (IRI).

Insights

Transcutaneous interferential electrical stimulation effectively improved constipation in children after Hirschsprung

Area of Science:

  • Pediatric Surgery
  • Gastroenterology
  • Neuromodulation

Background:

  • Hirschsprung's disease (HD) often leads to persistent constipation in children post-surgery.
  • Managing constipation in these patients requires effective therapeutic strategies.

Purpose of the Study:

  • To evaluate the efficacy of transcutaneous interferential (IF) electrical stimulation as an adjunct therapy for constipation in postoperative HD patients.

Main Methods:

  • A randomized controlled trial involving 30 HD children with constipation.
  • Interferential electrical stimulation combined with behavioral therapy versus behavioral therapy alone.
  • Assessment included anorectal manometry, bowel diaries, constipation scores, and pain scores pre- and post-treatment.

Main Results:

  • 66% of patients receiving IF stimulation showed improved constipation symptoms compared to 26.6% in the control group at 6 months (P<0.03).
  • The IF group experienced a significant increase in defecation frequency (P<0.009) and a decrease in pain scores (P<0.05).

Conclusions:

  • Transcutaneous interferential electrical stimulation is a beneficial addition to behavioral therapy for managing constipation in postoperative HD patients.
  • IF stimulation offers a promising non-invasive approach to improve bowel function and reduce pain.
Abstract

Related Concept Videos

Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.1K
Irritable Bowel Syndrome III: Medical and Nursing Management01:30

Irritable Bowel Syndrome III: Medical and Nursing Management

Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
961
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
811
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
1.0K
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation01:30

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
1.0K
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
842